Physician profile
Mark David Lafuria
NPI 1427181908
$8,562.94
in general payments reported to CMS, 2019-2025
41 companies · $977 in 2025
The $977 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,383 · 2020: $886 · 2021: $1,253 · 2022: $1,178 · 2023: $1,509 · 2024: $1,377 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,340.05 | 2019-2025 | Lokelma, Farxiga, Breztri |
| Lilly USA, LLC | $929.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $756.92 | 2019-2025 | |
| Novo Nordisk INC | $753.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $501.62 | 2019-2025 | Trintellix |
| Amgen INC. | $487.36 | 2020-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $404.40 | 2019-2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $358.98 | 2019-2023 | |
| Axsome Therapeutics, INC. | $338.47 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $305.88 | 2019-2025 | |
| Esperion Therapeutics, INC. | $305.06 | 2020-2024 | Nexletol |
| Allergan, INC. | $267.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.53 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $144.49 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $129.15 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lafuria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.